MAPK/ERK as a biomarker for cisplatin resistance in squamous cell carcinoma (SCC).

2625 Background: Significant progress in therapy of non SCC of the lung has been made through genomic profiling and subtyping according to oncogenic drivers. In SCC, cisplatin-based therapy remains the mainstay, and resistance to treatment is common. We sought to understand the molecular underpinnings of cisplatin resistance in SCC. Methods: SCC of patients were characterized by Next-Generation Sequencing. In vitro drug sensitivity in lung SCC cell lines (n= 3) was determined by MTS assay, transcriptomic analysis was performed with microarray and signalling regulation was investigated with phospho-kinase array. Cisplatin-mediated cellular signalling identified by transcription and phospho-kinase array was validated in SCC cell lines by Western blotting (n= 3). Expression of p-Erk in SCC specimens was detected with IHC staining. Results: We verified the paucity of oncogenic driver mutations in 45 lung SCC specimens. H596, H1869, H226 and ChaGo-k-1 cell lines were deemed sensitive while Calu-1, H2170, SW900...